Merck acquiring Avalon lysosomal disorder play Calporta

Keen to take advantage of the rising importance of autophagy, Merck has acquired Avalon Ventures-backed Calporta for up to $576 million. Based on research from the University of Michigan, Calporta has preclinical compounds against TRPML1, a key ion channel in autophagy, to treat lysosomal storage and neurodegenerative disorders, including Alzheimer’s

Read the full 500 word article

How to gain access

Continue reading with a
two-week free trial.